TScan Therapeutics, Inc. (TCRX) Dividend History

Company News

• TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

  TScan Therapeutics, a clinical-stage biotechnology company, announced updates from its PLEXI-T solid tumor and ALLOHA heme Phase 1 clinical trials, and plans to file an IND application for TSC-102-A0301 (CD45; HLA-A*03:01) with the FDA.

  GlobeNewswire Inc.
• New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs

  The article discusses the growing cancer treatment market, with a focus on companies like Oncolytics Biotech, Akoya Biosciences, Quanterix, TScan Therapeutics, and Arcellx. It highlights new data and collaborations that signal a turning point for precision-driven cancer biotechs.

  Benzinga

  Featured Companies: ACLX AKYA ONCY QTRX
• TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

  TScan Therapeutics, a clinical-stage biotechnology company, announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting. The presentation will focus on CD45 as a universal target for adjuvant TCR-T cell therapy following allogeneic hematopoietic cell transplantation.

  GlobeNewswire Inc.
• TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight

  The T-cell receptor (TCR) therapy pipeline is rapidly expanding, with over 80 pharmaceutical companies actively developing more than 100 TCR therapies for various cancers, including solid tumors. Several promising pipeline candidates are in different stages of clinical trials, showcasing the potential of TCR therapy to revolutionize cancer treatment.

  GlobeNewswire Inc.

  Featured Companies: IMTX
• TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

  TScan Therapeutics, a clinical-stage biotechnology company, announced that it will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025. The company is focused on developing T cell receptor-engineered T cell therapies for cancer treatment.

  GlobeNewswire Inc.